Ignite Creation Date:
2024-10-25 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06569498
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-28
Brief Title:
Neoadjuvant Triple Therapy for Resectable HCC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Neoadjuvant Transcatheter Arterial Chemoembolization Combined With Lenvatinib Plus Cadonilimab for Resectable Hepatocellular Carcinoma A Single-Arm Phase II Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TALENP001
Brief Summary:
This study is a single-arm multi-center prospective phase II trial aimed at evaluating the efficacy and safety of neoadjuvant therapy with transarterial chemoembolization TACE combined with lenvatinib and camrelizumab triple therapy in patients with resectable hepatocellular carcinoma HCC The study plans to enroll 20 patients The primary endpoints are major pathological response MPR rate and safety while the secondary endpoints are recurrence-free survival RFS objective response rate ORR R0 resection rate and overall survival OS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None